Background & Summary
====================

Malignant gliomas are the most common and lethal primary brain tumours. According to the multicentre cross-sectional study on brain tumours (MCSBT) in China, age standardized prevalence of primary brain tumours is approximately 22.52 per million for all populations, and that of gliomas is 31.1% in those aged 20--59 years^[@b1]^. Although there have been advances in the current standard of care, the survival for patients with gliomas has still remained unchanged, especially for aggressive gliomas^[@b2],[@b3]^. High-throughput whole-transcriptome sequencing technologies, i.e., RNA-seq, have the capability to capture the transcriptomic landscape with an unprecedented high-resolution. RNA-seq technology is able to generate comprehensive transcriptomic information at different levels, including quantification of protein-coding and non-coding gene expression, identification of non-coding RNAs (ncRNAs) and/or fusion genes, and determination of alternative splicing^[@b4],[@b5]^. Using RNA-seq to catalog abnormal events in the malignant progression of gliomas, from low-grade to high-grade dynamic range, can provide insights into disease susceptibility and identification of biomarkers, and could improve the translation of basic medicine to clinical therapy.

As a part of the Chinese Glioma Genome Atlas (CGGA, <http://cgga.org.cn/>) project, an RNA-seq profiling dataset for Chinese glioma patient cohort was generated to identify oncogenic fusions associated with glioma progression as previously described^[@b5]^. We revealed a novel, recurrent PTPRZ1-MET (ZM) fusion transcript in secondary glioblastomas, which was independently validated in other groups^[@b6]^. By combining this dataset with paired protein data, we also indicated that enhanced MET oncoprotein expression and phosphorylation were induced by glioma-specific ZM fusions^[@b7]^. To the best of our knowledge, this dataset represent the largest public RNA-seq data on Chinese glioma patient cohort. The principal aim of this study was to provide a comprehensive resource to deposit the raw RNA-seq data sets underpinning the advanced studies on dynamic transcriptomic signatures with the malignant progression of human gliomas. To this end, a total of three hundred and twenty five clinical samples were collected from several hospitals in China. These samples were chosen as they represented glioma patients with different grades of disease progression, allowing comparison of low-grade samples to their high-grade counterparts. The histopathological grades for these samples were as follows: 109 samples of grade II, 72 samples of grade III, and 144 samples of grade IV. As one of the deadliest cancers, grade IV glioma, termed glioblastoma (GBM), has a poor median survival time of only 12 to 18 months^[@b2],[@b8]^. Although most GBMs are primary, approximately twenty percent of them are secondary from the progression of previous low-grade gliomas of grade II or III^[@b11]^. Therefore, it is becoming an urgent clinical task to identify early biomarkers for diagnosis and prognosis, as well as to explore the mechanisms underlying the development and progression of gliomas. This data set will therefore be of important and indispensable values for the glioma research community at large.

In this work, the RNA-seq libraries were sequenced using the Illumina HiSeq 2,000 platform. Approximately 30 billion 101-bp paired-end RNA-seq reads were generated, with an average of over 92 million sequence reads per sample. For each sample, we first aligned the raw reads to the genome using MapSplice (v2.1.7)^[@b12]^ and annotated the reads to RefSeq, resulting in 17,527 genes. Next, we developed a web-based, user-friendly human glioma transcriptomic profiling database (GLIOMASdb, <http://cgga.org.cn:9091/gliomasdb/>) to deposit and catalog the transcriptomic profiles of the cohort of 325 glioma samples. In a few words, we have provided a comprehensive RNA-seq data resource on the malignant progression of Chinese glioma, which is useful to understand the progression of the disease. Furthermore, the data resource provides an opportunity to identify the biomarkers of early warning, diagnosis and prognosis, which have the potential to be applied to clinical treatments of glioma.

Methods
=======

Clinical specimen collection
----------------------------

A total of 325 glioma samples were obtained from several hospitals in China from 2004 to 2016. All research performed was approved by the Tiantan Hospital Institutional Review Board (IRB) and kept consistent with the principles of the Helsinki Declaration. All the subjects were diagnosed with gliomas by consensus, according to central pathology reviews by independent board-certified neuropathologists and further graded based on the 2007 WHO classification. Written informed consent was obtained from all patients. The specimens were collected under IRB KY2013-017-01 and were frozen in liquid nitrogen within 5 min of resection. The following clinical information of each patient was also collected: age, sex, diagnosis, WHO grade, chemoradiotherapy and epilepsy therapy status, etc. ([Table 1](#t1){ref-type="table"}).

RNA-seq library preparation and sequencing
------------------------------------------

Prior to library preparation, total RNA was isolated using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Pestle and QIAshredder (Qiagen) were used to disrupt and homogenize frozen tissue. The RNA intensity was checked using a 2,100 Bioanalyzer (Agilent Technologies) and only high quality samples with an RNA Integrity Number (RIN) value greater than or equal to 6.8 were used to construct the sequencing library. Typically, 1 μg of total RNA was used with the TruSeq RNA library preparation kit (Illumina) in accordance with low-throughput protocol, except that SuperScript III reverse transcriptase (Invitrogen) was used to synthesize first strand cDNA. After PCR enrichment and purification of adapter-ligated fragments, the concentration of DNA with adapters was determined with quantitative PCR (Applied Biosystems 7,500) using primers QP1 5′-AATGATACGGCGACCACCGA-3′ and QP2 5′-CAAGCAGAAGACGGCATACGAGA-3′. The length of the DNA fragment was measured using a 2,100 Bioanalyzer, with median insert sizes of 200 nucleotides. Then, RNA-seq libraries were sequenced using the Illumina HiSeq 2,000 Sequencing System. The libraries were prepared using the paired-end strategy with the read length of 101 bp. Base-calling was performed by the Illumina CASAVA v1.8.2 pipeline. The quality of the RNA-seq libraries was first evaluated using the FastQC v0.11.5 software (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/>) ([Fig. 1](#f1){ref-type="fig"}). Then, the reads were subjected to standard quality control (QC) criteria according to the following parameters: (1) reads that aligned to primers and/or adaptors with no more than two mismatches, (2) reads with over 50% of low-quality bases (quality value ≤5) in one read, and (3) reads with over 10% unknown bases (N bases). After QC, over 30 billion filtered reads were used for further analysis.

RNA-seq data analysis
---------------------

RNA-seq mapping and quantification were processed according to the pipeline in our previous research^[@b7]^. RNA-seq data from 325 grade II-IV gliomas was obtained from the Chinese Glioma Genome Atlas (CGGA) project. Applying the same TCGA mRNA-seq pipeline (University of North California RNA-seq workflow), expression analysis was performed with modifications. First, clean reads were aligned to the human genome reference (hg19) with MapSplice (v2.1.7)^[@b12]^, followed by BAM file sorting with SAMtools (v0.1.9)^[@b13]^. Second, sequencing read counts for each RefSeq gene were calculated using RSEM (v1.2.15)^[@b14]^. Third, expression levels from different samples were normalized by the Trimmed Mean of M values (TMM) method^[@b15]^. Finally, the normalized expression levels of different samples were merged into a FPKM (fragments per kilobase transcriptome per million fragments) matrix for further analysis.

Differential expression analyses were performed to reveal critical genes associated with the malignant progression of gliomas by comparing gene expression in pairwise grades of gliomas. A gene was defined to be associated with the malignant progression of gliomas only if it presented differential expression in the comparison of any two grades. It was required for the genes of differential expression to satisfy both *P*-value and fold-change criteria simultaneously (\|log2(Fold change)\|≥1 and FDR\<0.05). The *P*-values were obtained using the unpaired Student's *t*-test and the false discovery rate (FDR) was controlled by the Benjamini and Hochberg algorithm.

A database for human gliomas on RNA-seq
---------------------------------------

To facilitate community-wide use of this unique RNA-seq data on the malignant progression of gliomas, we have developed a free, web accessible, user-friendly transcriptomic profiling database (GLIOMASdb, <http://cgga.org.cn:9091/gliomasdb/>) for Chinese gliomas. Here, users can easily explore the expression patterns of gene of interest (e.g., mRNA or lncRNA) in the malignant progression of gliomas using the BROWSE interface. In addition, GLIOMASdb currently provides data download including gene expression profiles and matched phenotypic data.

Code availability
-----------------

The code is available on the *Figshare* (Data Citation 1).

Data Records
============

The raw fastq files for the RNA-seq data from the 325 gliomas in different stages of malignant progression, as part of the CGGA data sets, have been deposited in the SRA website (NCBI-SRA) under accession numbers SRP027383 (Data Citation 2) and SRP091303 (Data Citation 3). In addition, the complete datasets, including expression profiles (Data Citation 1) and matched clinical information (Data Citation 1), are available on the *Figshare* or downloaded from the GLIOMASdb web site: <http://cgga.org.cn:9091/gliomasdb/>.

Technical Validation
====================

Quality control---RNA integrity
-------------------------------

To determine the quality of the RNA-seq libraries, RNA intensity was checked using a 2,100 Bioanalyzer (Agilent Technologies). The integrity of the total RNA was calculated by the RNA Integrity Number (RIN) algorithm, which can be used to estimate RNA quality and degradation level. Higher RIN values indicate better integrity of total RNA, with the highest RIN value being 10. In this study, only total RNAs with a RIN value of greater than or equal to 6.8 were used to construct the sequencing library, which shows RNA with high integrity was used.

Quality validation and analyses
-------------------------------

We applied FastQC v0.11.5 software to determine data quality and analysed several measures, including the sequence quality per base, GC content per sequence, sequence duplication levels, and quality score distribution over all sequences of the fastq files. A representative summary plot is depicted (CGGA_909). Here, the quality scores per base were high, with a median quality score above 30 suggesting high quality sequences across all bases ([Fig. 1a](#f1){ref-type="fig"}). The GC distribution per base over all sequences was examined. The GC composition pattern was similar to theoretical distribution indicating that the samples were contaminant free ([Fig. 1b](#f1){ref-type="fig"}). In addition, sequence complexity was examined. Approximately 15% of sequences were shown over 10 to 100 times, either from highly expressed transcripts duplications ([Fig. 1c](#f1){ref-type="fig"}). The quality score distribution over all sequences was analysed to see if a subset of sequences had universally poor quality. The average quality for most sequences was high, with scores above 37, which indicated that a significant proportion of the sequences in a run had overall high quality ([Fig. 1d](#f1){ref-type="fig"}). All other fastqc files were shown to have similar quality metrics compared to sample CGGA_909.

The aim of this study was to depict the comprehensive RNA-Seq transcriptomic profiling of Chinese gliomas. For the analyses we chose samples from grade II-IV gliomas based on central pathology reviews by independent board-certified neuropathologists and the 2007 WHO classification. All are human gliomas, differing in molecular pathology, primarily in terms of malignant progression and possible genetic background. Using a heatmap depicting differentially expressed genes using one-dimensional hierarchical clustering analysis, one can intuitively observe that samples along the malignant progression gradient showed different expression patterns ([Fig. 2](#f2){ref-type="fig"}). Previously, Cheng *et al.* ^[@b16]^ showed eight immune-related genes (FOXO3, IL6, IL10, ZBTB16, CCL18, AIMP1, FCGR2B, and MMP9) with the greatest prognostic value in grade IV gliomas. Most of which (6/7, no data for FCGR2B in this study) we confirmed were differentially expressed between different grades of gliomas.

Usage Notes
===========

A wide range of public software, e.g., MapSplice^[@b12]^, TopHat^[@b17]^, RSEM^[@b14]^, Cufflinks^[@b18]^, could be used for transcript assembly and quantification. Other public software combinations could be efficiently used for quantification: e.g., HISATs^[@b19],[@b20]^ and StringTie^[@b21]^ for quantification, used together with the ballgown package^[@b19],[@b22]^ for differential expression analyses. Currently, several gene annotations are available, such as RefSeq, UCSC, and Ensembl. With the rapid development of RNA-seq technology, we also recommend use of the more comprehensive gene annotation generated from the GENCODE^[@b23]^ project, that reveals many new classes of RNAs, including pseudogenes and different types of ncRNAs.

A major advantage of this study is that we aimed to comprehensively profile the RNA-seq transcriptome along the malignant progression of gliomas. Consistent with previous research, we identified a set of differentially expressed genes involved in gliomas that may be biomarkers and therapeutic targets. However, there are several existing classifications for human gliomas, including Kernohan, AANS and excellent WHO grade classification. Although these classifications are able to simply recognize the malignant degree of gliomas, they cannot accurately determine the prognosis of patients and are not suitable for the current clinical treatments. We expect that other classification criterion will be developed based on the molecular pathology for understanding gliomas and precise medicines.
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![A representative example of quality control metrics of RNA sequenced reads as indicated by FastQC (sample: CGGA_909).\
(**a**) Phred quality score distribution over all reads in each base. (**b**) GC content (%) distribution over all sequences. (**c**) The distribution of duplicated reads compared to the total number of sequences. (**d**) Quality score distribution over all sequences.](sdata201724-f1){#f1}
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###### Patient Characteristics.

                                                 **All Patients (** ***N*** **=325)**  
  --------------------------------------------- -------------------------------------- -------
                                                            *Age classes*              
   \<18                                                           3                     0.92
   18--35                                                         71                    21.85
   36--39                                                         51                    15.69
   40--49                                                        103                    31.69
   50--59                                                         61                    18.77
   60--69                                                         31                    9.54
   ≥70                                                            5                     1.54
                                                                *Sex*                  
   Male                                                          203                    62.46
   Female                                                        122                    37.54
                                                         *WHO grade classes*           
   Grade II                                                      109                    33.54
   Grade III                                                      72                    22.15
   Grade IV                                                      144                    44.31
                                                            *TCGA classes*             
   Classical                                                      74                    22.77
   Mesenchymal                                                    68                    20.92
   Neural                                                         81                    24.92
   Proneural                                                     102                    31.39
                                                         *Chemoradiotherapy*           
   Radiotherapy plus other drugs                                  8                     2.46
   Radiotherapy plus temozolomide                                 78                    24.00
   Radiotherapy plus unknown drug                                 64                    19.69
   Chemotherapy with temozolomide alone                           12                    3.69
   Chemotherapy with unknown drug alone                           14                    4.31
   Radiotherapy alone                                             87                    26.77
   No data for radiotherapy plus temozolomide                     1                     0.31
   Radiotherapy plus no data for chemotherapy                     2                     0.62
   No data for chemoradiotherapy                                  27                    8.31
   No therapy                                                     32                    9.84
                                                          *Epilepsy therapy*           
   Anti-epileptic                                                 85                    26.15
   No therapy                                                    157                    48.31
   No data                                                        83                    25.54
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